|Trade names||Hytrin, Zayasel, others|
|Elimination half-life||12 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||387.440 g·mol−1|
|3D model (JSmol)|
Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.
Common side effects include dizziness, headache, tiredness, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder. It is used in the treatment of benign prostatic hyperplasia and the frequent urination that occurs in patients with that indication.
Terazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2018, it was the 198th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
It is available in 1 mg, 2 mg, 5 mg or 10 mg doses.
Reaction of piperazine with 2-furoyl chloride followed by catalytic hydrogenation of the furan ring leads to 2. This, when heated in the presence of 2-chloro-6,7-dimethoxyquinazolin-4-amine (1) undergoes direct alkylation to terazosin (3).